ArticleJournal of clinical microbiology1995
Utility of recombinant flagellar calcium-binding protein for serodiagnosis of Trypanosoma cruzi infection.
Article in Journal of clinical microbiology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas disease: a scoping review.Frontiers in microbiology · 2024Article
- Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure.PLoS neglected tropical diseases · 2022Article
- Article
- Article
- A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection.PLoS neglected tropical diseases · 2019Article
- Advances in nanocarriers as drug delivery systems in Chagas disease.International journal of nanomedicine · 2019Review
- Targeting host mitochondria: A role for the Trypanosoma cruzi amastigote flagellum.Cellular microbiology · 2018Article
- Article
- Polyclonal antibodies for the detection of Trypanosoma cruzi circulating antigens.PLoS neglected tropical diseases · 2017Article
- Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.Advances in parasitology · 2017Review
- A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.Human vaccines & immunotherapeutics · 2016Article
- Characterization of Calflagin, a Flagellar Calcium-Binding Protein from Trypanosoma congolense.PLoS neglected tropical diseases · 2016Article
- Differential protein expression throughout the life cycle of Trypanosoma congolense, a major parasite of cattle in Africa.Molecular and biochemical parasitology · 2011Article
- Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection.Journal of clinical microbiology · 2006Article
- Use of full-length recombinant calflagin and its c fragment for improvement of diagnosis of Trypanosoma cruzi infection.Journal of clinical microbiology · 2005Article
- Mapping of B-cell epitopes in a Trypanosoma cruzi immunodominant antigen expressed in natural infections.Clinical and diagnostic laboratory immunology · 2005Article
- Molecular diagnosis of Chagas' disease and use of an animal model to study parasite tropism.Parasitology research · 2003Article
- Antibodies to an epitope from the Cha human autoantigen are markers of Chagas' disease.Clinical and diagnostic laboratory immunology · 2001Article
- Evaluation of recombinant antigens for serodiagnosis of Chagas' disease in South and Central America.Journal of clinical microbiology · 1999Article
- Evaluation of three commercial enzyme-linked immunosorbent assays for diagnosis of Chagas' disease.Journal of clinical microbiology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protozoan Trypanosoma cruzi is the causative agent of Chagas' disease, a major public health problem in Latin America and of growing concern in the United States as the number of infected immigrants increases. There is currently no testing of U.S. blood products for T. cruzi infection, and the best tests available, although highly sensitive, are not of high enough specificity to be useful for widespread screening of the blood supply in this country. Among the parasite antigens detected by sera of infected humans and mice, those in the range of 24 to 26 kDa are particularly reactive. With an aim of developing a sensitive, specific, recombinant antigen-based serologic test for T. cruzi infection, we used two antibody reagents specific for these 24- to 26-kDa antigens to isolate cDNA clones from a T. cruzi expression library. One clone was found to encode a previously characterized T. cruzi antigen, a 24-kDa flagellar calcium-binding protein (FCaBP). Recombinant FCaBP was found to be a sensitive, specific reagent for distinguishing T. cruzi-infected individuals from uninfected persons, and it therefore could potentially be used for screening purposes, especially if combined with other recombinant T. cruzi antigens that have similarly high degrees of diagnostic sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.